One possible mechanism of MYD88/CD79B-derived lymphomagenesis involves TLR/MYD88 signaling, which might initiate tumor growth in IP sites, characterized by their favorable microenvironments, whereas concomitant CD79B mutations could further promote lymphomagenesis by enhancing the BCR signaling [41]. The gene discussed is BCR; the disease is neoplasm.